Did You Know That Medicilon Can Handle DMPK Studies?

2024-10-22 Medicilon Preclinical Pharmacokinetics Department has many professional scientists with rich theoretical knowledge and experimental experience for experimental design, implementation, bioanalysis and data analysis. Our Pharmacokinetics Lab has passed the NMPA GLP certification. Following the guiding principles of ICH, NMPA and FDA . The lab offers in vivo and in vitro pharmacokinetic tests according to […]

Medicilon Supports Jemincare’s JMX-2002 Liposome Injection Clinical Trial Approval

2024-12-09 Shanghai, China – October 16, 2024 – Medicilon is pleased to announce that its long-term partner, Jemincare Group Co., Ltd. (“Jemincare”), has received clinical trial approval from the China National Medical Products Administration (NMPA) for its innovative liposome injection drug, JMX-2002, for the treatment of solid tumors, including non-small cell lung cancer and breast cancer. […]

Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts

2024-08-29 In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon’s continued global business expansion. Medicilon’s U.S. R&D Center The Lexington, MA location was chosen to enhance synergy and […]

Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout

2024-03-11 Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND […]

Medicilon 20th Anniversary – Keep pace with the times in innovation, thanks for having you

2024-02-28 In 2024, Medicilon will celebrate its 20th anniversary.  At the time of departure, Medicilon shouldered the dream of China’s new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream.  During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D […]

Medicilon’s GLP-1 New Drug R&D Service

2023-06-12 Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from “sugar control” to both “sugar control” and “heart protection”. GLP-1R agonists can improve left […]

Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

2023-05-19 Antibody-Oligonucleotide Conjugates (AOCs) represent an emerging class of functionalized antibodies that have already been used in a wide variety of applications. Combining the specific binding ability of antibodies with the vast structural and functional properties of oligonucleotides, these conjugates have found a wide variety of applications as imaging, detection and therapeutic agents. AOCs are […]

The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs

2023-01-05 Many impurities in drugs can produce toxic and side effects, which is a crucial factor affecting the safety and effectiveness of drugs, especially genotoxic impurities that can cause serious harm to human health with minimal exposure. Therefore, to ensure API quality and preparations, Genotoxic impurities are a class of impurities that must be paid attention […]

​Aim at chemical synthesis through Ibuprofen

2023-01-02 Recently, Pfizer’s new crown-specific drug Paxlovid and the national miracle drug Ibuprofen are the most popular drugs in the medical circle. Today we will talk about the synthesis and mechanism of action of Ibuprofen, an evergreen drug! Recently, Ibuprofen has been hard to find, and it has become a well-known hard currency. Ibuprofen Ibuprofen, […]

Search Medicilon

Medicilon Supports BIOTIME in Securing Dual China-US Approvals for CDC7 Inhibitor BIOT-006

BIK Therapeutics and Medicilon Sign Strategic Collaboration Agreement to Accelerate Oncology Drug Innovation.

Boston Innovation Meets ADME Precision

Contact Medicilon

Name
Address